Treating haematological cancers in Romania

The landscape of haematological cancers in India

Haematological malignancies: Latest advances from ASH 2019

Cancer care in Argentina

VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatment of AML

Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection

Dasatinib vs imatinib in the treatment of paediatric ALL

Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients

PET-Directed therapy for early-stage diffuse large B-cell lymphoma

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT treated with tabelecleucel

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo

Prognostic impact of chromosomal abnormalities and copy number alterations in B-cell precursor ALL treated on UKALL14

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?

Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity

Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial

Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM

Myeloma highlights from ASH 2019

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

FLT3-inhibition in infants with acute lymphoblastic leukaemia

Chronic lymphocytic leukaemia highlights from ASH 2019

Benefits of apixaban among venous thromboembolism patients with active cancer

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL

Dasatinib vs imatinib for paediatric Ph ALL

Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints

KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM

Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma

Eligibility criteria in acute myeloid leukaemia clinical trials

Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia

Azacitidine plus nivolumab in older adults with AML or MDS

Venetoclax chemo combo active and well-tolerated in children with r/r AML

Precision medicine treatment in older AML: Results of Beat AML master trial

Older patients with non-Hodgkin lymphoma can be treated successfully with CAR T-cell therapy

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents

Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma

Maintenance therapy with CC-486 for acute myeloid leukaemia

Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL

Multiple myeloma highlights from ASH 2019

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML

Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial

Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negative patients

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients

Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions

Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate

Cellular immunotherapy for B cell cancers shows promise